Forward Looking Statements This presentation contains certain forward looking statements, including those relating to the Company s product development, clinical and regulatory timelines, market opportunity, competitive

Vertex Kalydeco Cystic Fibrosis mutations of CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R $294,000 $1.2B** Conclusions Lead Product Resunab is a novel, safe and promisingly potent clinical stage anti inflammatory/anti fibrotic drug which acts to resolve inflammation Targets multiple rare chronic inflammatory indications Proven safe in two Phase 1 trials Promising potency in multiple pre clinical inflammatory/fibrotic models Launch two Phase 2 trials in 2015 (Cystic Fibrosis and Scleroderma) Completion of studies in 2016 Strong patent portfolio until 2033 25 26 100 River Ridge Drive Norwood, MA 02062 www.CorbusPharma.com

Hospital for Special Surgery NYC Professor of Medicine, Head of Scleroderma and Vasculitis Center Daniel Furst, M.D. UCLA School of Medicine Director of UCLA Scleroderma Program Robert Zurier, M.D. UMass Medical School Ex Chair of Rheumatology 21 Financial Profile OTCQB: CRBP 22 Stock Ticker: OTCQB: CRBP $77,400,000 Market capitalization as of November 5, 2014 $10,300,000 Raise from successful private placement (Q2 2014) from institutional and retail base 25,800,000 Common shares outstanding 41,500,000 Fully diluted shares outstanding (including warrants and stock options) $11,400,000 Available from exercise of callable warrants NASDAQ Up listing to NASDAQ planned by Q 1 2015 Q1 2015 File IND with FDA Q1+Q2 2015 Q1 2015 Plan to up list to NASDAQ H2 2016 Data from clinical trials 2014 2016 Oct 2014 Began trading on OTCQB 2015 Launch clinical trials Corbus Poised for Significant Upside 23 Recent Deals Date Company Partner Type Drug Indication Stage Up Front Deal Total 11/2014 Galecto BMS Option to acquire TD139 Idiopathic pulmonary fibrosis Phase 1 NA $444M* 8/2014 InterMune Roche Acquisition Esbriet Idiopathic pulmonary fibrosis Approved NA $8.3B* 9/2013 Galapagos AbbVie License GLPG1837 Mutations in CF patients, including F508del and G551D Pre clinical $45M* $405M* 7/2011 Amira BMS Acquisition AM152 Idiopathic pulmonary fibrosis and systemic sclerosis Phase 1 $325M* $475M* * Figures from company press releases $405 $444 $450 $8,300 $100 $1,000 $10,000 Galapagos (License AbbVie) Galecto (M A BMS) Amira (M A BMS) Intermune (M A Roche) Recent Deals in CF and Fibrosis Pre Clinical Phase 1 Phase 3 Potential Value Indicators 24 Recent IPO Date Company Lead Compound Indication Stage Market Cap 9/2014 ProQR QR 010 Cystic Fibrosis RNA repair Pre clinical $284.11M * Figures from company press releases ** Leerink analyst report Market Cap of CF and Fibrosis Focused Companies $286 $685 $1,347 $5,335 $26,000 $77 30 300 3000 30000 Corbus ProQR Insmed PTC Intercept Vertex Market Phase 3 PC Phase 2a Approved Products Company Drug Indication Cost per Year 2018 Sales Est.

Chapter of the Cystic Fibrosis Foundation World Class Scientific Advisors Sumner Burstein, Ph.D. UMass Medical School Professor of Biochemistry and Pharmacology; inventor of Resunab Michael Knowles, M.D., Ph.D. UNC Chapel Hill Professor of Pulmonary and Critical Care Medicine James Chmiel, M.D. Case Western Reserve Medical School Professor Medicine, National PI on largest ever anti inflammatory CF study Robert Spiera M.D.

Chief Executive Officer Avery W. (Chip) Caitlin Renu Gupta, M.D. David Hochman Amb. Alan Holmer Chairman of the Board CFO Celldex Therapeutics (CLDX) since 2000 Raised over $415 MM financing 20 years experience in industry: Repligen (CFO) and Endogen (CFO) 25 years of development, regulatory and senior management experience in the biopharm industry Former CMO of Insmed, a specialty CF company and current advisor to the CEO Former Vice President and Head of US Clinical Research and Development at Novartis (2003 2006) Managing Partner of Orchestra Medical Ventures Over 17 years of venture capital and investment banking experience Former Managing Director of Spencer Trask Ventures, Inc. securing over $420 million in equity capital Former CEO of PhRMA (1996 2005) Over two decades of public service in Washington, D.C. including Special Envoy to China (2007 2009) Former board member Inspire Pharma (sold to Merck for $430m in 2011) Chairman of the Board of the Metropolitan Washington, D.C.

Investigator, Bristol Myers Squibb Expertise in developing anti inflammatory drugs including for CF Co founder and former President of Celsus Therapeutics (CLTX) Mark Tepper, Ph.D. President Chief Scientific Officer Yuval Cohen, Ph.D. Chief Executive Officer Sean Moran, C.P.A. M.B.A. Chief Financial Officer Barbara White, M.D. Chief Medical Officer Board of Directors 20 Yuval Cohen, Ph.D.

Previously held positions in industry: SVP and Head, R D for Stiefel a GSK company, VP and Head of Inflammation Clinical Development at UCB and MedImmune/AstraZeneca, and Director, Medical Affairs, Amgen Former CFO: InVivo (NVIV), Celsion (CLSN), Transport Pharma, Echo Therapeutics (ECTE) Anika Therapeutics (ANIK) Key member of project teams which developed the following marketed drugs: Taxol (Ovarian Cancer, 2000 peak sales of $1.6B), Orencia (RA, 2013 sales of $1.4B), Rebif (MS, 2013 sales of $2.59B), Gonal F (Fertility, 2013 sales of $815MM) Former VP USA Research Operations, EMD Serono; Sr.

Kalydeco by Vertex priced at $320,000/yr) CFTR gene defect Underlying Inflammation Infection Fibrosis 11 Antibiotics Kalydeco (for 6%) Resunab Resunab Resunab targets key CF inflammatory players 11 TGF Lipoxin A4 Genetically linked to disease Associated with worsening symptoms Absent in CF lungs CFTR defect Underlying Inflammation Infection Fibrosis Replacement therapy effective in animal models Fibrosis inducing agent (Bleomycin) administered to lungs day 1 followed by daily oral Resunab for 21 days P .004 Bleomycin+ Resunab therapy Bleomycin Control Gonzales et.al., Annals of Rheumatic Diseases, 2012. 71:1545 51 * Measured by hydroxyproline Alveoli air sacs Resunab Reduces Pulmonary Fibrosis In Animal Models Control Bleomycin Bleomycin + Resunab (1mg/kg) 12 0 50 100 150 200 250 300 350 Resunab Planned Cystic Fibrosis Phase 2 Trial 13 Double blind randomized placebo control study in the US and EU Primary endpoints: Safety/tolerability Secondary endpoints: Pharmacokinetics and efficacy (FEV1, Lung Clearance Index, CFQ R Respiratory Domain) Exploratory endpoints: Metabolipidomic profile for MOA, biomarkers of disease activity in blood and sputum, biomarkers of inflammation, and microbiota in the lungs Patient number: 70 adults with CF in ~20 sites US EU Treatment duration: 3 months + 1 month follow up Dose response: 1 mg/day, 5 mg/day, 20 mg/day and 2x20 mg/day Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 Protocol filed with FDA X Study launches X First patient dosed X Study duration X X X X X X Last patient dosed X Study data released X Diffuse Systemic Sclerosis ( Scleroderma ) Relief for a disease with no effective long term therapy 14 Overview: Diffuse Cutaneous Systemic Sclerosis (Scleroderma) 15 Chronic inflammatory disease causing fibrosis of skin, joints and internal organs Orphan disease (50,000 patients in USA) 80% of patients are women in their 40 s, 50 s and 60 s Common cause of death: lung fibrosis (50% mortality in 10 years) Early stage of disease responds to steroids/methotrexate but with serious side effects No effective and safe long term therapy available Pipelines often target Idiopathic Pulmonary Fibrosis (IPF) in conjunction to SSc Resunab Inhibits Key Factors in SSc TGF beta plays key role in SSc progression (same in CF and IPF) Elevated TGF beta levels associated with disease progression Strong Resunab efficacy data in animal models Resunab reduces TGF beta and collagen in skin fibroblasts from SSc patients TGF beta Collagen Concentration of Resunab ( M) Concentration of Resunab ( M) Healthy skin fibroblasts Scleroderma patients skin fibroblasts 0 50 100 150 200 250 300 350 400 0 0.1 1 5 10 0 5 10 15 20 25 30 35 40 45 0 0.1 1 5 10 16 Resunab Inhibits Skin Thickening In Mouse SSc Model Gonzales et.al., Annals of Rheumatic Diseases, April 4, 2012 17 Control Bleomycin Bleomycin + Resunab Thick skin induced by Bleomycin Near normal skin after oral Resunab taken once daily for four weeks Healthy skin 0 100 200 300 400 500 Resunab : Planned SSc Phase 2 Clinical Trial 18 Double blind placebo control randomized study in USA under IND from FDA Primary end points: Safety/tolerability + Change in clinical outcomes (CRISS) Secondary end points: Metabolipodomic profile + biomarkers of disease activity inflammation + quality of life (QOL) Patient number: 36 adults with SSc with 8 10 US sites Treatment duration: 3 months + 1 month follow up Dose response: 5mg/day, 20mg/day and 20mg/2Xday Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 Protocol filed with FDA X Study launches X First patient dosed X Study duration X X X X X X Last patient dosed X Study data released X Management Team 19 Rheumatologist and immunologist.

The Company undertakes no obligation to publicly update any forward looking statement, whether as a result of new information, future events or otherwise. 3 Overview Corbus Pharma is focusing on rare, life threatening, chronic inflammatory diseases Lead drug Resunab : a first in class oral anti inflammatory/fibrosis small molecule Acts to trigger inflammatory resolution: the off switch for chronic inflammation Proven safe in Phase 1 + promising pre clinical potency in multiple animal models Phase 2 clinical trials to commence 2015: Successful $10.3m private financing round (May 2014) Obtained $1.3m in NIH grants IP protection until 2033 and potentially longer Commenced trading on OTCQB in October 2014 Cystic Fibrosis (CF) Systemic Sclerosis (SSc) also known as Scleroderma Our Target Indications: Current Future Indication Patient numbers (USA) Estimated Market size Current therapies for inflammation Drawbacks to current therapies Current lead indications: Cystic Fibrosis 30,000 $3B Steroids, ibuprofen Considerable side effects Diffuse Systemic Sclerosis (Scleroderma) 50,000 $2B Steroids, methotrexate Side effects, poor efficacy Potential future indications: Dermatomyositis 13,000 $1B Steroids, mAbs Side effects, poor efficacy Lupus (SLE) 500,000 1.5MM $3B Steroids, mAbs Side effects, poor efficacy Idiopathic Pulmonary Fibrosis (IPF) 70,000 $1B Pirfenidone Limited efficacy InterMune bought by Roche for $8.5B (2014) 4 Inflammation ON Pro inflammatory Mediators ( IL6, IL8, PGE2, LTB4) Immune cell TGF CB2 receptor Inflammation OFF Fibrosis ON Fibrosis OFF CB2 receptor is present on immune cells and activated by endogenous lipid mediators Activation of CB2 turns inflammation off ( inflammatory resolution ) Resunab expected to be first CB2 binding anti inflammatory drug to reach market Upstream of other approaches: potential for better safety and potency CB2 Receptor: Turns inflammation off Immune cell COX LOX LXA 4 Anti inflammatory Mediators (Lipoxins, Resolvins, etc) 5 6 7 Resunab 7 Resunab: synthetic oral CB2 agonist small molecule Designed to trigger the resolution of chronic inflammation Full manufacturing, drug supply, non clinical safety pharmacology package for Phase 2 programs Excellent clinical safety profile to date: two prior Phase 1 clinical trials (n=123) Preparing to launch two Phase 2 clinical studies in H1 2015 8 Resunab : Only CB2 Agonist Targeting Inflammation Company Indication Brain penetration Status Affects CNS Corbus Pharma Inflammation Minimal Entering Phase 2 No AbbVie Pain Full Phase 1 Yes Glenmark Pain Full Phase 1 Yes Eli Lilly Knee pain Full Phase 2 Yes AstraZeneca Post operative pain Full Phase 2 Yes Resunab is the only CB2 drug that can be used to treat inflammation because it does not target the brain 9 Cystic Fibrosis Targeting inflammation at the core of the disease 9 10 Antibiotics Kalydeco (for 6%) of patients Very limited treatment No treatment Overview: Cystic Fibrosis 10 Orphan disease (30,000 patients in USA, 75,000 WW) Average life expectancy of CF patients is approximately 40 years Inflammation at core of disease s morbidity and mortality (pulmonary fibrosis) Very high doses of steroids/ibuprofen effective but rarely used due to toxicity Need for safe, chronic anti inflammatory drug is unmet and universally recognized Pharmacoeconomics support premium pricing (e.g.

These statements involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward looking statements. Prospective investors are cautioned not to place undue reliance on such forward looking statements, which speak only as of the date of this presentation.

Additional written and oral forward looking statements may be made by the Company from time to time in filings with the Securities and Exchange Commission (SEC) or otherwise. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward looking statements. These statements may be identified by the use of forward looking expressions, including, but not limited to, expect, anticipate, intend, plan, believe, estimate, potential, predict, project, should, would, will and similar expressions and the negatives of those terms.

Developing Breakthrough Therapies for Rare Inflammatory Diseases www.CorbusPharma.com OTCQB: CRBP Exhibit 99.1 2 Forward Looking Statements This presentation contains certain forward looking statements, including those relating to the Company s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature.